Frontline Nab-Paclitaxel/Gemcitabine in Metastatic Pancreatic Cancer | OncLive

Frontline Nab-Paclitaxel/Gemcitabine in Metastatic Pancreatic Cancer

September 29, 2016

Gerrit zur Hausen, MSc, clinical trial manager, Epidemiologe, Institut für Klinisch-Onkologische Forschung, discusses a trial exploring frontline treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic adenocarcinoma who have high-bilirubin levels.

Gerrit zur Hausen, MSc, clinical trial manager, Epidemiologe, Institut für Klinisch-Onkologische Forschung, discusses a trial exploring frontline treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic adenocarcinoma who have high-bilirubin levels.

The multicenter observational German study, titled QoliXane, is assessing quality of life and therapy data, zur Hausen explains. Researchers are also collecting available tumor tissues for further analyses. In the current interim analysis, patients with high baseline bilirubin level were studied.

Results showed that approximately 9% to 10% of the patients enrolled in the study had a high baseline bilirubin level. Seventy percent of these patients started therapy at a normal dose, while the remaining 30% started at a lower dose level. Additionally, more than half of these patients received a secondary intervention, including stenting or bile duct anastomosis, he adds.


x